Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related P...(rysm or bulging of the major artery wh...),Health

Date:9/28/2007

rysm, or "bulging" of the major artery which arises from the heart, is a serious condition prone to rupture and sudden death. According to the Society for Vascular Surgery, less than half of all patients who experience a rupture of a thoracic aortic die before reaching the hospital, making it the 13th leading cause of death in the U.S. Furthermore, studies report that emergent, open surgical repair of a ruptured thoracic aneurysm carries a 25 to 50 percent risk of death. ELGs, which are metal stents covered by a fabric graft material, offer a lower-risk alternative to open surgical repair. The device is delivered under X-ray guidance via a catheter passed through an artery near the groin. The ELG is then positioned and expanded within the aorta at the site of the problem, restoring blood flow, providing significant pain relief and reducing the risk of rupture. Depending on their general condition, patients typically return home within a few days.

"It is evident that ELGs represent an important means of treating thoracic aortic pathologies," said Venkatesh G. Ramaiah, M.D., study co-author and director of Peripheral Vascular and Endovascular Research at the Arizona Heart Institute. "To date, this is the largest published series of patients treated with thoracic ELGs for a variety of thoracic aortic pathologies. After more than 500 cases performed at the Arizona Heart Institute, complication rates, including death, compare favorably with open surgical repair, suggesting that endoluminal grafting is a favorable alternative in the treatment of thoracic aortic pathologies," said Ramaiah.

"We are very pleased with the results from this important study which further supports the movement toward minimally invasive management of aortic disease," said Edward B. Diethrich, M.D., medical director, founder of the Arizona Heart Institute and study author. "Since the early 1990s, we have pioneered a multitude of new technologies, treatments and therapies for cardiovasc
'/>"/>

SOURCE The Arizona Heart Institute Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting